ERBB2 and breast carcinoma: Other HER2‐targeted drugs used for the treatment of metastatic breast cancer, like lapatinib and more recently and even more efficiently tucatinib27 (in combination with trastuzumab and capecitabin) and trastuzumab deruxtecan,28 have shown promising treatment results in patients with HER2+ breast cancer and brain metastases.